Lilly Announces Increased Access to Clinical Trials Data for Qualified Researchers
Eli Lilly and Company has announced it will begin sharing its clinical trial data with scientific researchers through www.clinicalstudydatarequest.com. This website, which houses data from several clinical trial sponsors, was created in support of ongoing efforts by the Pharmaceutical Research and Manufacturers of America (PhRMA) and the European Federation of Pharmaceutical Industries and Associations (EFPIA) to increase access to and transparency of clinical trial results with researchers around the world.
"Scientific advancements to improve patient care require the collaboration and creative thinking of researchers around the world. Since our early partnership with academic researchers brought about the first commercial insulin, we've continued to seek new ways to bring our internal expertise together with the high-quality research being done beyond our walls," said Tim Garnett, MD, senior vice president and chief medical officer, Eli Lilly and Company.
"By joining others in our industry to share clinical trial data with qualified researchers, we can quicken the pace of scientific advances needed to make life better."
The new portal differs from previous Lilly data-sharing sites in that access will only be granted after approval of a research proposal by an independent scientific review panel. Lilly will not be involved in the decisions made by the independent scientific review panel.
The multi-sponsor portal will include Lilly-sponsored interventional clinical studies from approved medicines and indications in the US and EU in the following categories:
• Phase II, III or IV studies used as part of a regulatory approval submitted to FDA on or after 1999
• Phase II, III or IV global studies with a first patient visit after 1 January 2007
• Phase II, III or IV global or regional/local studies in indications approved in both the US and EU with a first patient visit after 1 January 2014.
All shared data on the website are anonymized to safeguard patients' privacy.
Former Lilly Clinical Trial Websites to Be Replaced
As part of Lilly's commitment to open access and transparency, the company established www.lillyclinicalstudydata.com in January 2014 to facilitate researchers' requests for data from interventional clinical trials for approved medicines and indications. However, this website was an interim solution as Lilly worked with others in the pharmaceutical industry to create coordinated access to data from multiple study sponsors. Now that this coordinated access is available, Lilly will replace the current web site, www.lillyclinicalstudydata.com, with the newly announced www.clinicalstudydatarequest.com.
Lilly also provides information on and links to information about its clinical studies on www.LillyTrials.com. The website includes results of all Lilly-sponsored Phase II, III and IV clinical trials as well as observational trials of Lilly-marketed products conducted anywhere in the world that were initiated on or after 15 October 2002.
Related News
-
News Understanding the Benefits and Advances of Cleanroom Technology
In an industry where precision and sterility are crucial concerns, cleanrooms play a vital role in maintaining the integrity of pharmaceutical products like drugs, vaccines, and other medical products. So, what is a cleanroom?
-
News AbbVie secures GBP£1.2 billion deal for Gilgamesh’s psychedelic programme
AbbVie has penned a significant agreement to acquire the bretisilocin programme from Gilgamesh Pharmaceuticals for up to £1.2 billion, marking a bold step in the pharmaceutical giant's quest to develop treatments for psychiatric disorders. -
News Gates Foundation commits US$2.5 billion to women’s health research
The Bill & Melinda Gates Foundation has announced a substantial US$2.5 billion commitment to accelerate research and development focused exclusively on women's health through 2030.
-
News Mid-year review: notable FDA drug approvals of 2025
As we fly past the halfway point of 2025, the pharmaceutical landscape reliably continues to evolve with innovative therapies addressing critical medical needs. The FDA has already approved 17 groundbreaking medications this year, each representin... -
News US FDA announces new priority vouchers for accelerated review times
The US FDA announced a new priority program for drug developers – the Commissioner’s National Priority Voucher (CNPV) program aims to enhance the health interests of the US by allowing drug developers to redeem a voucher, shortening th... -
News Google-backed start-up raises US$600 million to support AI drug discovery and design
London-based Isomorphic Labs, an AI-driven drug design and development start-up backed by Google’s AI research lab DeepMind, has raised US$600 million in its first external funding round by Thrive Capital. The funding will provide further power t... -
News AstraZeneca to invest US$2.5 billion in Beijing R&D centre
Amid investigations of former AstraZeneca China head Leon Wang in 2024, AstraZeneca have outlined plans to establish its sixth global strategic R&D centre in China. Their aim is to further advance life sciences in China with major research and manufact... -
News Experimental drug for managing aortic valve stenosis shows promise
The new small molecule drug ataciguat is garnering attention for its potential to manage aortic valve stenosis, which may prevent the need for surgery and significantly improve patient experience.